WALLEN WILLIAM C
Form 4
July 31, 2009

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *
WALLEN WILLIAM C

(Last) (First) (Middle)

C/O IDEXX LABORATORIES INC, ONE IDEXX DRIVE

(Street)

WESTBROOK, ME 04092

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [IDXX]

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2008

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__X__ Officer (give title below)
_____ Other (specify below)
SVP & Chief Scientific Officer

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/29/2009		M		15,000	A	$ 21.3	32,114 (2)	D	
Common Stock	07/29/2009		S		15,000	D	$ 49.7397 (1)	17,114	D	
Common Stock	07/29/2009		M		1,500	A	$ 21.3	18,614	D	
Common Stock	07/30/2009		M		5,000	A	$ 21.3	23,614	D	
	07/30/2009		S		5,000	D	$ 49.8	18,614	D	

Common Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun Underlying Securit (Instr. 3 and 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh
Incentive Option (right to buy)	$ 21.3	07/29/2009		M			1,500	(3)	09/08/2013	Common Stock	1,5
Non-Qualified Stock Option (right to buy)	$ 21.3	07/29/2009		M			15,000	(3)	09/08/2013	Common Stock	15,0
Non-Qualified Stock Option (right to buy)	$ 21.3	07/30/2009		M			5,000	(3)	09/08/2013	Common Stock	5,0

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
WALLEN WILLIAM C C/O IDEXX LABORATORIES INC ONE IDEXX DRIVE WESTBROOK, ME 04092			SVP & Chief Scientific Officer	

Signatures

John B. Rogers, Attorney-in-Fact for William C. Wallen, PhD	07/31/2009
**Signature of Reporting Person	Date

Explanation of Responses:

***** If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sales price reported above reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged between $49.65 and $49.85. Reporting person hereby undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.

(2) Includes 110 shares of common stock acquired pursuant to the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2009.

(3) Grant of options to purchase shares of common stock becomes exercisable in five equal increments, beginning on the first anniversary date (9/8/2004) of the date of the grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.